[ad_1]
Plaintiff’s motion for summary judgment. Merck & Co., Inc., v. Xavier Becerra et al. US District Court for the District of Columbia (11 July 2023).
Duehren, A., Wise, L. & Rubin, R. Democrats reach deal on lowering prescription drug prices. Wall Street Journal (2 November 2021).
Pharmaceutical Research and Manufacturers of America. ICYMI: a Patient, Physician, Biotech Investor and Industry Leaders Warn About the Dangers of Government Price Setting Bill https://catalyst.phrma.org/icymi-a-patient-physician-biotech-investor-and-industry-leaders-warn-about-the-dangers-of-government-price-setting-bill (2022).
Biotechnology Innovation Organization. New Drug Pricing Bill Could Propel Us Light Years Back into the Dark Ages of Biomedical Research https://www.bio.org/press-release/new-drug-pricing-deal-could-propel-us-light-years-back-dark-ages-biomedical-research (2022).
Kolchinsky, P. et al. Healthcare Investors Make a Case for a Simple Fix: Parity of ‘Negotiation’ for All Drugs at 13 Years https://nopatientleftbehind.docsend.com/view/e4cg7sgj6js5qenr (2022).
Buxbaum, J., Chernew, M., Fendrick, A. & Cutler, D. Contributions of public health, pharmaceuticals, and other medical care to US life expectancy changes, 1990–2015. Health Aff. 39, 1546–1556 (2020).
Cutlerc, D., Rosen, A. & Vijan, S. The value of medical spending in the United States, 1960–2000. N. Engl. J. Med. 355, 920–927 (2006).
United States Government Accountability Office. Drug Industry: Profits, Research and Development Spending, and Merger and Acquisition Deals. GAO-18-40 https://www.gao.gov/products/gao-18-40 (2017).
Dusetzina, S., Huskamp, H., Qin, X. & Keating, N. Prescription drug spending in fee-for-service Medicare, 2008–2019. JAMA 328, 1515–1522 (2022).
Congressional Budget Office. Estimated Budgetary Effects of Public Law 117-169 https://www.cbo.gov/system/files/2022-09/PL117-169_9-7-22.pdf (2022).
Congressional Budget Office. CBO’s Model of New Drug Development https://www.cbo.gov/publication/57450 (2022).
Philipson, T. & Durie, T. Issue Brief: the Impact of HR 5376 on Biopharmaceutical Innovation and Patient Health https://cpb-us-w2.wpmucdn.com/voices.uchicago.edu/dist/d/3128/files/2021/08/Issue-Brief-Drug-Pricing-in-HR-5376-11.30.pdf (2021).
Gassull, D., Bowen, H., & Schulthess, D. IRA’s Impact on the US Biopharma Ecosystem https://vitaltransformation.com/2023/05/iras-impact-on-the-us-biopharma-ecosystem (2023).
Dickson, S. & Hernandez, I. Drugs likely subject to Medicare negotiation, 2026–2028. J. Manag. Care Spec. Pharm. 29, 229–235 (2023).
Rome, B. et al. Simulated Medicare drug price negotiation under the Inflation Reduction Act of 2022. JAMA Health Forum 4, e225218 (2023).
Reitsma, M. et al. Examining opportunities to increase savings from Medicare price negotiations. JAMA Intern. Med. 183, 581–588 (2023).
Schuhmacher, A. et al. The significance of blockbusters in the pharmaceutical industry. Nat. Rev. Drug Discov. 22, 177–178 (2023).
Evaluate Pharma. World Preview 2022, Outlook to 2028: Patents and Pricing https://info.evaluate.com/rs/607-YGS-364/images/2022%20World%20Preview%20Report.pdf (2022).
Hernandez, I., San-Juan-Rodriguez, A., Good, C. & Gellad, W. Changes in list prices, net prices, and discounts for branded drugs in the US, 2007–2018. JAMA 323, 854–862 (2020).
Brown, A. The Patent Winter is Coming https://www.evaluate.com/vantage/articles/insights/other-data/patent-winter-coming (2022).
Dixit, R. & David, F. Market watch: trends in pharmaceutical company R&D spending: 2005–2015. Nat. Rev. Drug Discov. 16, 376 (2017).
Elmhirst, E. COVID Drives a Record Jump in Research Spending for Big Pharma https://www.evaluate.com/node/17806/pdf (2022).
Joint Committee on Taxation. Memorandum: Analysis of Large Pharmaceutical Corporation Tax Data https://www.finance.senate.gov/imo/media/doc/JCT%20-%20pharma%20tax%20data%205.4.23.pdf (2023).
Krieger, J., Li, X. & Thakor, R. Find and Replace: R&D Investment Following the Erosion of Existing Products Working Paper 19-058 (Harvard Business School, 2021).
Ringel, M. What is the right amount to spend on biopharma R&D? Nat. Rev. Drug Discov. 16, 597–598 (2017).
Yin, W. Market incentives and pharmaceutical innovation. J. Health Econ. 27, 1060–1077 (2008).
Blume-Kohout, M. & Sood, N. Market size and innovation: effects of Medicare Part D on pharmaceutical research and development. J. Public Econ. 97, 327–336 (2013).
Agha, L., Kim, S., & Li, D. Insurance design and pharmaceutical innovation. Am. Econ. Rev. Insights 4, 191–208 (2022).
Branstetter, L., Chatterjee, C., & Higgins, M. Generic Competition and the Incentives for Early-Stage Pharmaceutical Innovation Working Paper 20532 https://www.nber.org/system/files/working_papers/w20532/w20532.pdf (NBER, 2022).
Vogel, M., Kesselheim, A., Feldman, W. & Rome, B. Will Medicare price negotiation delay cancer-drug launches? N. Engl. J. Med. 389, 1546–1548 (2023).
Congressional Budget Office. How CBO Estimated the Budgetary Impact of Key Prescription Drug Provisions in the 2022 Reconciliation Act https://www.cbo.gov/system/files/2023-02/58850-IRA-Drug-Provs.pdf (2023).
Frank, R., McGuire, T. & Nason, I. The evolution of supply and demand in markets for generic drugs. Milbank Q. 99, 828–852 (2021).
Vogel, M. et al. Cost of exempting sole orphan drugs from Medicare negotiation. JAMA Intern. Med. 184, 63–69 (2024).
Abbott, T. & Vernon, J. The cost of US pharmaceutical price regulation: a financial simulation model of R&D decisions. Manage. Decis. Econ. 28, 293–306 (2007).
Kerr, W. & Nanda, R. Financing innovation. Annu. Rev. Financ. Econ. 7, 445–462 (2015).
Fougner, C. et al. Herding in the drug development pipeline. Nat. Rev. Drug Discov. 22, 617–618 (2023).
Bloom, N., Schankerman, M. & Van Reenen, J. Identifying technology spillovers and product market rivalry. Econometrica 81, 1347–1393 (2013).
Dranove, D., Garthwaite, C. & Hermosilla, M. Does consumer demand ‘pull’ scientifically novel drug innovation? Rand J. Econ. 53, 590–638 (2022).
Byrski, D., Gaessler, F. & Higgins, M. Market Size and Research: Evidence from the Pharmaceutical Industry Working Paper 28858 https://www.nber.org/system/files/working_papers/w28858/w28858.pdf (National Bureau of Economics Research, 2021).
Frank, R., Conti, R. & Gruber, J. International reference pricing in the context of US drug policy. J. Health Polit. Policy Law 47, 779–796 (2022).
Conti, R., Frank, R. & Nichols, L. How do commercial insurance plans fare under proposed prescription drug price regulation? JAMA Health Forum 2, e214242 (2021).
Adler, L. Cost-Shifting in Drug Pricing, or the Lack Thereof https://www.brookings.edu/articles/cost-shifting-in-drug-pricing-or-the-lack-thereof (2021).
Clemens, J. & Gottlieb, J. In the shadow of a giant: Medicare’s influence on private physician payments. J. Polit. Econ. 125, 1–39 (2017).
Dusetzina, S., Keating, N., Huskamp, H. & Mello, M. Medicare’s plan for drug-price negotiation: the importance of defining generic entry. N. Engl. J. Med. 389, 97–100 (2023).
Rome, B., Egilman, A. & Kesselheim, A. Trends in prescription drug launch prices, 2008–2021. JAMA 327, 2145–2147 (2022).
Congressional Budget Office. Re: Additional Information About Drug Price Negotiation. https://www.cbo.gov/system/files/2023-12/59792-Letter.pdf (2023).
Cha, M., Rifai, B. & Sarraf, P. Pharmaceutical forecasting: throwing darts? Nat. Rev. Drug Discov. 12, 737–738 (2013).
DiMasi, J., Grabowski, H. & Hansen, R. Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ. 47, 20–33 (2016).
Wouters, O., McKee, M. & Luyten, J. Estimated research and development investment needed to bring a new medicine to market, 2009–2018. JAMA 323, 844–853 (2020).
Frank, R. & Zeckhauser, R. Excess Prices for Drugs in Medicare: Diagnosis and Prescription Working Paper RWP18-005 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3116330 (Harvard Kennedy School, 2018).
Maqvi News #Maqvi #Maqvinews #Maqvi_news #Maqvi#News #info@maqvi.com
[ad_2]
Source link
